Clone 29F.1A12 has been validated for use on CODEX® using mouse spleen fresh frozen (FF) tissue.
FF (Fresh Frozen)
Antibody and Reporter Details
PD-1 cDNA followed by PD-1-Ig fusion protein
This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4.
Storage and Handling
This antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Applications and Recommended Usage?
Quality Tested by Leinco
CODEX® This CD279/PD-1 (Clone 29F.1A12) antibody is formulated to simplify the antibody preparation needed when performing a CODEX® barcode conjugate. The suggested concentration is 0.5 mg/ml.
Country of Origin
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Clone 29F.1A12 recognizes an epitope on mouse PD-1.
PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells.
PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.
B7-H1 (PD-L1) and B7-DC (PD-L2)
Lymphocyte clonal selection, peripheral tolerance
NCBI Gene Bank ID
Products are for research use only. Not for use in diagnostic or therapeutic procedures.